For research use only. Not for therapeutic Use.
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pKa of AFMK at physiological pH is 8.7. Antioxidant capacity[1][2]. AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway[3].
AFMK is one of the metabolites of melatonin and can be formed by both enzymatic or pseudoenzymatic and nonenzymatic metabolic pathways[1].
AFMK pretreatment significantly inhibits DNA damage. AFMK shows a very high level of in vitro hydroxyl radical scavenging potential which was measured by an electron spin resonance (ESR) study. IC50 values resulting from ESR analysis was 338.08 nM. AFMK, a melatonin metabolite, is a sparingly investigated biogenic amine[2].
AFMK administered to PANC-1 in combination with Gemcitabine inhibits the production of HSP70 and cIAP-2 as compared to the results obtained with Gemcitabine alone[3].
AFMK is a potent antioxidant in vivo. AFMK significantly reverses radiation-induced decline in the total antioxidant capacity of plasma in mice[2].
| Catalog Number | R001284 |
| CAS Number | 52450-38-1 |
| Synonyms | N-[3-(2-formamido-5-methoxyphenyl)-3-oxopropyl]acetamide |
| Molecular Formula | C13H16N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H16N2O4/c1-9(17)14-6-5-13(18)11-7-10(19-2)3-4-12(11)15-8-16/h3-4,7-8H,5-6H2,1-2H3,(H,14,17)(H,15,16) |
| InChIKey | JYWNYMJKURVPFH-UHFFFAOYSA-N |
| SMILES | CC(=O)NCCC(=O)C1=C(C=CC(=C1)OC)NC=O |
| Reference | [1]. Annia Galano, et al. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J Pineal Res. 2013 Apr;54(3):245-57. [2]. Kailash Manda, et al. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res. 2007 Apr;42(4):386-93. [3]. Anna Leja-Szpak, et al. Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1). Pharmacol Rep. 2018 Dec;70(6):1079-1088. |
